{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:19:22Z","timestamp":1780471162162,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.clml.2021.10.014","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T13:00:14Z","timestamp":1635771614000},"page":"e285-e292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-3171","authenticated-orcid":false,"given":"Hamid","family":"Ehsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-3304","authenticated-orcid":false,"given":"Abdul","family":"Rafae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-777X","authenticated-orcid":false,"given":"Adeel","family":"Masood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Khawar","family":"Sana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqraa","family":"Ansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-5287","authenticated-orcid":false,"given":"Karun","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arooj","family":"Umar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrat","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.10.014_bib0001","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0002","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J clin oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.014_bib0003","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2019.218859","article-title":"Predicting survival in light chain amyloidosis","volume":"104","author":"Palladini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.10.014_bib0004","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2021.10.014_bib0005","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol (Baltimore, Md. : 1950)"},{"key":"10.1016\/j.clml.2021.10.014_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.10.014_bib0007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/10428194.2016.1228926","article-title":"Treatment options for relapse after autograft in multiple myeloma\u2013report from an EBMT educational meeting","volume":"58","author":"Garderet","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.10.014_bib0008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13506129.2020.1730791","article-title":"Treatment with daratumumab in patients with relapsed\/refractory AL amyloidosis: a multicentric retrospective study and review of the literature","volume":"27","author":"Lecumberri","year":"2020","journal-title":"Amyloi"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.10.014_bib0009","first-page":"508","article-title":"A prospective phase ii of daratumumab in previously-treated systemic light-chain (AL) amyloidosis","volume":"130","author":"Roussel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0010","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0011","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ajh.25828","article-title":"High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate","volume":"95","author":"Milani","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.10.014_bib0012","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2019.10.019","article-title":"Dual monoclonal antibody therapy in patients with systemic AL amyloidosis and cardiac involvement","volume":"20","author":"Godara","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.10.014_bib0014","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/bloodadvances.2019000776","article-title":"Organ responses with daratumumab therapy in previously treated AL amyloidosis","volume":"4","author":"Chung","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.014_bib0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hon.2677","article-title":"Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden","volume":"37","author":"Schwotzer","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2021.10.014_bib0016","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.15455","article-title":"Daratumumab proves safe and highly effective in AL amyloidosis","volume":"185","author":"Khouri","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2021.10.014_bib0017","first-page":"1836","article-title":"Daratumumab monotherapy in thirty-two heavily pre-treated patients with advanced systemic light-chain amyloidosis","volume":"130","author":"Kimmich","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0018","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.10.014_bib0019","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.10.014_bib0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0021","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/13506129.2020.1765768","article-title":"Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed\/refractory AL amyloidosis","volume":"27","author":"Cohen","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.clml.2021.10.014_bib0022","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/10428194.2020.1850717","article-title":"Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment","volume":"62","author":"Gounot","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.10.014_bib0023","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0024","first-page":"184","article-title":"Daratumumab for relapsed AL amyloidosis\u2014When cumulative real-world data precedes clinical trials:","volume":"106","author":"Shragai","year":"2021","journal-title":"A multisite study and systematic literature review"},{"key":"10.1016\/j.clml.2021.10.014_bib0025","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.014_bib0027","first-page":"212","article-title":"When should treatment of AL amyloidosis start at relapse?","volume":"3","author":"Palladini","year":"2019","journal-title":"Early, to prevent organ progression"},{"key":"10.1016\/j.clml.2021.10.014_bib0028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:44Z","timestamp":1761871124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021024174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2152265021024174"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.10.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}